Skip to content

US · RANI · BIOTECHNOLOGY

Rani Therapeutics Holdings, Inc. (RANI) intrinsic value and stock valuation

$0.51as of 2026-11-21 · Mkt cap 51.73M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rani Therapeutics Holdings, Inc. DCF and intrinsic value

InvestorsCraft values RANI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RANI’s statements →

Rani Therapeutics Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Jose, CA 95131 ranitherapeutics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$1.63M+28.8% 5y CAGRd
20192025
Net income
-$-29.67M
20192025
Free cash flow
-$-18.8M
20192025
Total equity
$41.5M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$1.63M$1.03M$0.00$0.00$2.72M
Operating income-$-38.31M-$-53.31M-$-66.1M-$-63.45M-$-51.6M
Net income-$-29.67M-$-30.02M-$-33.97M-$-30.59M-$-8.33M
EPSd-$-448.59K-$-1.05M-$-1.33M-$-1.28M-$-426.52K
Operating cash flow-$-18.71M-$-35.5M-$-51.24M-$-46.52M-$-32.24M
Capital expenditure-$-90K-$-270K-$-1.23M-$-1.62M-$-510K
Free cash flow-$-18.8M-$-35.76M-$-52.47M-$-48.13M-$-32.75M
Total assets$58.6M$36.6M$57.9M$108M$124.2M
Total debt$4.32M$29.7M$30.1M$30.2M$0.00
Net debt-$-14.3M$26M$24.2M$3.21M-$-117.45M
Total equity$41.5M$3.49M$25.4M$74M$121.6M
Cash and short-term investments$49.7M$27.6M$48.5M$98.5M$117.5M
Income statement
20252024202320222021
Revenue$1.63M$1.03M$0.00$0.00$2.72M
Cost of revenue$900K$0.00$820K$0.00$0.00
Gross profit$730K$1.03M-$-820K$0.00$2.72M
Research and development expenses$20.2M$26.7M$39.6M$36.6M$26.5M
Selling, general and administrative expenses$19.7M$24M$26.5M$26.8M$27.8M
Other expenses-$-900K$3.71M-$-820K$0.00$0.00
Operating expenses$39M$54.3M$65.3M$63.5M$54.3M
Cost and expenses$39.9M$54.3M$66.1M$63.5M$54.3M
Interest income$830K$1.76M$3.3M$1.25M$90K
Interest expense$2.89M$5.03M$5.08M$1.07M$470K
Depreciation and amortization$900K$1.03M$820K$550K$500K
Ebitda-$-37.16M-$-50.52M-$-61.98M-$-61.66M-$-52.08M
Operating income-$-38.31M-$-53.31M-$-66.1M-$-63.45M-$-51.6M
Total other income/expenses, net-$-2.64M$23.3M-$-1.78M$180K-$-1.45M
Income before tax-$-40.95M-$-30.02M-$-67.88M-$-63.27M-$-53.05M
Income tax expense$0.00$26.6M$0.00$70K$40K
Net income-$-29.67M-$-30.02M-$-33.97M-$-30.59M-$-8.33M
Weighted average shares outstanding$66.1M$28.5M$25.5M$23.8M$19.5M
Weighted average diluted shares outstanding$66.1M$28.5M$25.5M$23.8M$19.5M
Balance sheet
20252024202320222021
Cash and short-term investments$49.7M$27.6M$48.5M$98.5M$117.5M
Net receivables$2.04M$430K$200K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$53.3M$29.7M$50.9M$100.9M$119.6M
Property, plant and equipment, net$5.05M$6.64M$6.82M$7.1M$4.61M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.3M$6.89M$7.07M$7.1M$4.61M
Total assets$58.6M$36.6M$57.9M$108M$124.2M
Accounts payable$310K$1.36M$650K$1.46M$1.08M
Short-term debt$1.59M$16.5M$5.62M$1.01M$0.00
Deferred revenue$6.83M$0.00$1.21M$0.00$0.00
Total current liabilities$12.7M$19.9M$7.99M$4.82M$2.64M
Long-term debt$2.73M$13.3M$24.5M$29.2M$0.00
Deferred revenue, non-current$1.71M$0.00$0.00$0.00$0.00
Total non-current liabilities$4.44M$13.3M$24.5M$29.2M$0.00
Capital lease obligations$1.59M$5.1M$720K$1.06M$0.00
Total liabilities$17.1M$33.1M$32.5M$34M$2.64M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-132.58M-$-102.91M-$-72.89M-$-38.92M-$-8.33M
Accumulated other comprehensive income (loss)$0.00$10K-$-10K-$-70K-$0.00
Total equity$41.5M$3.49M$25.4M$74M$121.6M
Total investments$31.1M$23.9M$42.7M$71.5M$0.00
Total debt$4.32M$29.7M$30.1M$30.2M$0.00
Net debt-$-14.3M$26M$24.2M$3.21M-$-117.45M
Cash flow statement
20252024202320222021
Net income-$-29.67M-$-56.58M-$-33.97M-$-63.34M-$-8.33M
Depreciation and amortization$900K$1.03M$820K$550K$500K
Stock-based compensation$11.8M$16M$19M$15.8M$22.6M
Change in working capital$6.96M-$-540K-$-2.14M$510K-$-3.43M
Accounts receivable-$-1.61M-$-430K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.05M$710K-$-590K$160K$540K
Net cash provided by operating activities-$-18.71M-$-35.5M-$-51.24M-$-46.52M-$-32.24M
Investments in property, plant and equipment-$-90K-$-270K-$-1.23M-$-1.62M-$-510K
Acquisitions, net$0.00$0.00$0.00-$-850K$0.00
Net cash used for investing activities-$-7.03M$19.8M$29.9M-$-72.44M-$-510K
Common stock issued$61.1M$18.6M$400K$320K$73.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$40.3M$13.6M$230K$29M$77.2M
Net change in cash$14.6M-$-2.1M-$-21.14M-$-89.95M$44.4M
Cash at end of period$18.8M$4.26M$6.36M$27.5M$117.5M
Operating cash flow-$-18.71M-$-35.5M-$-51.24M-$-46.52M-$-32.24M
Capital expenditure-$-90K-$-270K-$-1.23M-$-1.62M-$-510K
Free cash flow-$-18.8M-$-35.76M-$-52.47M-$-48.13M-$-32.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rani Therapeutics Holdings, Inc.

        Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

        CEO
        Talat Imran
        Employees
        71
        Beta
        0.69

        Explore

        Frequently asked questions

        What is the intrinsic value of Rani Therapeutics Holdings, Inc. (RANI)?

        InvestorsCraft does not currently publish an intrinsic value for RANI. How the IC value is calculated.

        Is RANI undervalued?

        InvestorsCraft does not publish an undervaluation signal for RANI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.